You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

 

Online download statistics by month:

Online download statistics by month: January 2020 to March 2024

AbstractFullPdf
Jan 202015150
Feb 202090900
Mar 202066664
Apr 202044446
May 202042427
Jun 202038388
Jul 2020393922
Aug 2020323216
Sep 2020555546
Oct 2020606062
Nov 2020444436
Dec 2020353527
Jan 2021909039
Feb 2021414148
Mar 2021525240
Apr 2021414135
May 2021666649
Jun 2021444426
Jul 2021171719
Aug 2021292923
Sep 2021636341
Oct 2021757660
Nov 2021545440
Dec 2021454535
Jan 2022545527
Feb 20229610035
Mar 2022464615
Apr 2022727829
May 2022606529
Jun 2022535419
Jul 202229309
Aug 2022585828
Sep 2022656626
Oct 2022495123
Nov 2022595920
Dec 2022767722
Jan 2023515222
Feb 2023434523
Mar 2023656521
Apr 2023333416
May 2023282812
Jun 2023394019
Jul 2023555523
Aug 2023434418
Sep 2023464612
Oct 2023262613
Nov 202336379
Dec 2023797918
Jan 2024545418
Feb 2024494912
Mar 2024586016
Total259926311223